US maker of gene-mapping tools, Illumina Inc. (ILMN) has been targeted for a takeover by Roche Holding AG (ROG), and shareholders are eager to play their hand. (STAY AHEAD OF THE CURVE: Follow Kapitall on Twitter)
Illumina’s share price rose above the big price, indicating investors are betting an even higher offer will come, reports Bloomberg. Illumina currently trades at $52.06, above the newest offer price of $51 a share Roche’s shares have fell 1.75% on Thursday.
Illumina shareholders believes Roche will quickly fold and raise the bid price higher, and feel confident they are in a good position to ask for it. After all, there are few other bidders for Illumina so they can afford to hold out until Roche comes back with a better offer.
“As long as their stock is trading higher than Roche’s offer, they don’t have to do anything,” said Dan Leonard, an analyst with Leerink Swann & Co. to Bloomberg.
Well played, Illumina, well played.
Business Section: Investing Ideas
So, how will this tug-of-war over bid price end?
Here are some tools from Kapitall to help you follow the progress and learn more about the companies involved.
Click through to customize the metrics, add more companies and access more free tools on Kapitall.
Compare changes in market cap:
Compare changes in average analyst recommendation:
See changes in performance against the Standard & Poor 500 index:
Written by Rebecca Lipman